ABPI responds to NICE's VBA consultation
Future looks bleak for universal healthcare in Australia
Are prescription charges worth it for UK's NHS?
Gilead asked to explain $US84 000 price-tag for Sovaldi
New NICE guidance for preventing strokes in AF patients
Biomarker-directed therapy: testing times
WHO issues HCV guidelines despite drug cost controversy
BRAF-targeted therapies: cost effective for metastatic melanoma?
Canagliflozin makes cost-effective impact in the US
Biosimilar erythropoietin uptake not linked to price
Aortic valve implantation misses the beat in Spain
How to stop the bleeding in Colombia
Guanfacine's stimulating results in Canada
NICE being too nice with end-of-life treatments?
Older is better with herpes zoster vaccination in adults
Is FMT cost effective in C. difficile infection?
When one is better than many in HIV
Solifenacin/tamsulosin FDC squeezes out competitors
Antidepressant use and suicidal behaviour after FDA warnings
Human fibrinogen to the rescue in Mexico
Cost drivers for reperfusion therapy in acute stroke
Cost of infection in patients with PIDD substantial in the US
Drug marketing: negative effects on prescribing choices
FOLFOX cost effective in elderly patients with colon cancer
Mumps vaccination programmes cost saving in Japan
Men B vaccine: cost perceived as strong barrier to prescribing
Hepatitis and flu immunisation rates of HIV-infected patients low
Rotavirus vaccination reduces healthcare resource use in the US
Primary DM/CKD care suboptimal in Indigenous Australians
Severe refractory asthma costly in the UK
Significant financial burden for cancer survivors
Secondary prevention suboptimal in ACS in Australia, New Zealand
UK cancer research equals health gains, good economic return
Will US policymakers see the light with anti-VEGF therapy?
Substantial benefits from early vaccination for flu pandemic
India to expand its price caps to include more drugs
Tecfidera to be reimbursed for MS patients in British Columbia
NICE supports spine-straightening device for scoliosis ...
Vertex signs letter of intent for ivacaftor in Canada